Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study

BACKGROUND: Diroximel fumarate (DRF) is a novel oral fumarate approved for relapsing forms of multiple sclerosis (MS). DRF demonstrated significantly improved gastrointestinal (GI) tolerability versus dimethyl fumarate (DMF) with fewer days of Individual Gastrointestinal Symptom and Impact Scale (IG...

Descripción completa

Detalles Bibliográficos
Autores principales: Wundes, Annette, Wray, Sibyl, Gold, Ralf, Singer, Barry A., Jasinska, Elzbieta, Ziemssen, Tjalf, de Seze, Jerome, Repovic, Pavle, Chen, Hailu, Hanna, Jerome, Messer, Jordan, Miller, Catherine, Naismith, Robert T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985943/
https://www.ncbi.nlm.nih.gov/pubmed/33796143
http://dx.doi.org/10.1177/1756286421993999

Ejemplares similares

Ejemplares similares